Dr Elisa Agostinetto

Go Back

Medical Oncologist and Research Fellow

  • Institut Jules Bordet
  • location Belgium

Dr Elisa Agostinetto is a medical oncologist and leading researcher in the field of breast cancer. She received her medical degree in Italy, at University of Udine. She completed her training in medical oncology in Milan, Italy, and afterwards she moved to Brussels, Belgium, where she is currently pursuing an advanced research fellowship at Institut Jules Bordet - Université Libre de Bruxelles.

Dr Elisa Agostinetto has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Sandoz, AstraZeneca; support for conference attendence from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, AstraZeneca and a research grant to her institution from Gilead.

Programmes developed by Dr Elisa Agostinetto

conference-update Conference update
Oncology 
Highlights from ESMO 2025

Experts join us at ESMO 2025 to share their views on new data on GU, lung, breast, gynecological and upper GI cancers

Experts
Dr Herbert Loong, Prof. Viktor Grünwald, Prof. Thomas Powles, Dr Elisa Agostinetto, Prof. Nicoletta Colombo, Dr Elizabeth Smyth
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

NSCLC and RCC updates supported by Independent Education Grants from Bayer and Eisai Europe Ltd. respectively. All other updates supported by COR2ED.
ipcv Interactive Patient Case Video (IPCV)

Episode

1

of 2

episode
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1

An interactive patient case video series from breast cancer specialists

Experts
Dr Elisa Agostinetto
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Sep 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology